These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9528837)

  • 1. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
    Knoop A; Andreasen PA; Andersen JA; Hansen S; Laenkholm AV; Simonsen AC; Andersen J; Overgaard J; Rose C
    Br J Cancer; 1998 Mar; 77(6):932-40. PubMed ID: 9528837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
    Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
    BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
    Deluche E; Venat-Bouvet L; Leobon S; Fermeaux V; Mollard J; Saidi N; Jammet I; Aubard Y; Tubiana-Mathieu N
    BMC Cancer; 2017 Sep; 17(1):662. PubMed ID: 28954632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
    Uhl B; A Mittmann L; Dominik J; Hennel R; Smiljanov B; Haring F; B Schaubächer J; Braun C; Padovan L; Pick R; Canis M; Schulz C; Mack M; Gutjahr E; Sinn P; Heil J; Steiger K; Kanse SM; Weichert W; Sperandio M; Lauber K; Krombach F; Reichel CA
    EMBO Mol Med; 2021 Jun; 13(6):e13110. PubMed ID: 33998175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
    Kubala MH; DeClerck YA
    Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
    BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.
    Tarighi P; Montazeri H; Khorramizadeh MR; Sobhani AM; Ostad SN; Ghahremani MH
    Res Pharm Sci; 2015; 10(3):200-5. PubMed ID: 26600846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
    Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C-δ mediates sepsis-induced activation of complement 5a and urokinase-type plasminogen activator signaling in macrophages.
    Yang XS; Liu MY; Zhang HM; Xue BZ; Shi H; Liu DX
    Inflamm Res; 2014 Jul; 63(7):581-9. PubMed ID: 24682410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
    Botkjaer KA; Deryugina EI; Dupont DM; Gårdsvoll H; Bekes EM; Thuesen CK; Chen Z; Ploug M; Quigley JP; Andreasen PA
    Mol Cancer Res; 2012 Dec; 10(12):1532-43. PubMed ID: 23038812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System.
    Carter JC; Church FC
    J Oncol; 2011; 2011():594258. PubMed ID: 22131991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
    Botkjaer KA; Fogh S; Bekes EC; Chen Z; Blouse GE; Jensen JM; Mortensen KK; Huang M; Deryugina E; Quigley JP; Declerck PJ; Andreasen PA
    Biochem J; 2011 Aug; 438(1):39-51. PubMed ID: 21635223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.
    Cai T; Li X; Ding J; Luo W; Li J; Huang C
    Curr Cancer Drug Targets; 2011 Jun; 11(5):548-59. PubMed ID: 21486220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
    Dupont DM; Madsen JB; Hartmann RK; Tavitian B; Ducongé F; Kjems J; Andreasen PA
    RNA; 2010 Dec; 16(12):2360-9. PubMed ID: 20962041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.
    Carter JC; Church FC
    PPAR Res; 2009; 2009():345320. PubMed ID: 19672469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mode of intervention with serine protease activity: targeting zymogen activation.
    Blouse GE; Bøtkjaer KA; Deryugina E; Byszuk AA; Jensen JM; Mortensen KK; Quigley JP; Andreasen PA
    J Biol Chem; 2009 Feb; 284(7):4647-57. PubMed ID: 19047064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
    Dong Z; Saliganan AD; Meng H; Nabha SM; Sabbota AL; Sheng S; Bonfil RD; Cher ML
    Neoplasia; 2008 May; 10(5):439-49. PubMed ID: 18472961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease nexin-1 expression is altered in human breast cancer.
    Candia BJ; Hines WC; Heaphy CM; Griffith JK; Orlando RA
    Cancer Cell Int; 2006 May; 6():16. PubMed ID: 16737540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.
    Sakakibara T; Hibi K; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Br J Cancer; 2005 Oct; 93(7):799-803. PubMed ID: 16091756
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.